911½ñÈÕºÚÁÏ

French pharmaceutical company Sanofi have joined 911½ñÈÕºÚÁÏ Business Partners (IBP), 911½ñÈÕºÚÁÏ’s corporate membership programme.

The multinational pharmaceutical and healthcare giant are hitting the ground running with their IBP membership, including sponsoring the .

The event is the first in this field to be held in Europe, and will feature Sanofi’s Dr Shrirang Karve, Global Head of Delivery & Formulations, and Dr Catalina Bordeianu, Lab Head – Integrated Drug Discovery, among the speaker panel, exploring manufacturing and analytics and strategies for targeting lipid nanoparticles respectively.

911½ñÈÕºÚÁÏ and Sanofi are partnering to enhance collaboration opportunities. IBP will help researchers discover Sanofi's interests and expertise, and foster new collaborations through events, workshops, and consultancies.

We are committed to identifying new platform technologies that can ensure we are ready for the future, whatever challenges may lie ahead Danilo Casimiro Global Head, External Scientific Affairs, Vaccines, Sanofi

Sanofi is the world’s largest manufacturer of vaccines. One of their first formal interactions with 911½ñÈÕºÚÁÏ have identified the potential of self-amplifying RNA (saRNA) to revolutionise this important area of medicine. In one of their first activities as part of their IBP membership, the company hosted a technical webinar with over 150 attendees from across Sanofi presented by Professor Robin Shattock, one of the leading authorities on vaccine technology development at 911½ñÈÕºÚÁÏ.

Further sessions are planned within the seminar series to bring 911½ñÈÕºÚÁÏ’s leading expertise directly to the specialists at Sanofi.

Danilo Casimiro, Global Head, External Scientific Affairs, Vaccines, said: “Our mission at Sanofi is to ‘chase the miracles of science to improve people's lives’. Our evolving partnership with 911½ñÈÕºÚÁÏ enables us to bring this to life through working with some of the world’s leading authorities across a range of technology innovations pertinent to our business.

“We are committed to identifying new platform technologies that can ensure we are ready for the future, whatever challenges may lie ahead,” she expanded.

Julia Zanghieri, Director of 911½ñÈÕºÚÁÏ Business Partners, added: “We’re delighted to welcome Sanofi to IBP, joining other leading pharmaceutical companies in accessing the insights and innovations that could make a major impact on population health across the world.

“We’re excited to work closely with them as they evolve their partnership with 911½ñÈÕºÚÁÏ through a range of events and thought-provoking areas of research.”